Serial cranial computed tomograms were carried out in 136 children with acute lymphoblastic leukaemia who were receiving 24 Gy or 18 Gy of cranial irradiation and continuing treatment with doses of methotrexate given weekly orally or intramuscularly. The findings were correlated with treatment variables, the development of fits, and the inteliigence quotient (IQ). Reversible brain shrinkage, attributed to treatment with steroids, was found on 87 of 114 initial scans (76%); 14 showed changes in white matter during treatment (10%), and calcification was found in 13 either during or after treatment (10%). Eight children (6%) had fits, and in six of the eight there were changes in white matter or calcification on the scans. Comparison of the two radiotherapy dosages showed no difference in the incidence of abnormalities seen on computed tomography, fits, or serial IQ measurements, but children receiving intramuscular methotrexate had a higher incidence of calcification and a lower mean IQ at one year than those who received the drug orally, although this difference was not apparent later. Younger children were more likely to develop changes on computed tomograms and fits, and to have low IQs on completion of treatment, with changes most apparent in those less than 2 years of age. There were highly significant correlations between abnormalities on computed tomography, fits, and IQ. These findings confirm the neurological vulnerability of younger children with acute lymphoblastic leukaemia, show an association between abnormalities on computed tomography and intellectual deficit, and suggest that methotrexate is more toxic when given intramuscularly than orally. They 
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Results
One hundred and sixty four children were entered into the study, of whom 158 achieved remission. Three children with Down's syndrome and one whose mother had Down's syndrome were excluded from the study, together with one infant (the only patient in the series) in whom central nervous system disease was present at the time of first lumbar puncture. Seventeen patients were not available for computed tomography either because the parents did not consent to the investigation or they lived too far away, and thus this report concerns the remaining 136 ( at the time of diagnosis, and at one and two years.
Whereas there was an apparent slight increase in the mean IQs of children receiving methotrexate orally, those of children receiving methotrexate intramuscularly showed an apparent decrease. Analysis of variance showed no significant difference between these results. Estimation of the percentage increase in IQ from presentation to one year using the MannWhitney (non-parametric) test, showed a significant difference between the children receiving methotrexate orally and intramuscularly, but this difference was not sustained when the values at presentation and at two years were compared. There were no significant differences between the two radiotherapy groups.
RISK FACTORS FOR DEVELOPMENT OF ABNORMALITIES
There was no association between age at the time of diagnosis and the appearance of brain shrinkage on computed tomography, but younger children were significantly more likely to develop changes in white matter (p<0025), calcification, (p<0 025), fits (p<0.01), and hyperextensible joints (p<001) than older children; they were not, however, more likely to be clumsy. The IQ on completion of treatment was significantly lower (p=0 0006) in the under 2 year olds, and a regression analysis of IQ and age showed a significant correlation (p=001).
There was no association between any of the findings on computed tomography or any neurological abnormality, and the sex of the child.
Children who received 24 Gy of irradiation were at no more risk of abnormalities visible on scans than those receiving 18 Gy (table 6 ). Table  6 also shows the influence of route of administration of the methotrexate. Although more children who received methotrexate intramuscularly developed change in white matter (9/65 compared with 5/71), this difference was not significant, nor was the difference in the incidence of fits, but calcification was found more often in those receiving methotrexate intramuscularly (p=003). This significance disappeared when allowance was made for age.
INTER-RELATIONSHIP OF ABNORMALITIES (table 7)
There was no relationship between the presence of brain shrinkage on computed tomography and the development of fits or the assessment of IQ. There seemed to be an association between clumsiness on neurological follow up examination and the presence of atrophy on the final follow up scan. Children with change in white matter or calcification seen on the scan were significantly more likely to have fits, but there was no association between these findings and any other neurological symptoms. There was a highly significant correlation between the occurrence of fits during or after treatment and the IQ, and between these findings and changes on computed tomography.
PROBLEMS OF GROWTH AND DEVELOPMENT
Prospective assessment of endocrine function No that showed calcification 3 7 3 10 No that developed fits was not a part of this study. The youngest children have now reached the age of 9-10 years, and precocious or early puberty has been noted in nine girls and premature adrenarche in one boy. By contrast, we found some evidence that methotrexate given intramuscularly was more toxic than when given orally; more children receiving the drug intramuscularly developed attenuation of white matter and fits during or after treatment in association with abnormalities on scans. These results were not significant, but they are suggestive, particularly in view of the additional finding of increased calcification in the group receiving the drug intramuscularly. There was also some evidence that IQ measurements declined in children receiving methotrexate intramuscularly, although this finding was not sustained on longer follow up. Four of the five children who developed repeated fits in association with abnormalities on their scans were receiving methotrexate intramuscularly. Though all three of the five who survived have serious learning problems, none has the focal neurological abnormality or continued deterioration described in gross encephalopathy associated with higher dose methotrexate given intravenously.
Our analysis of the risk factors for neuropsychological damage in this study confirms once again the vulnerability of young children, but not that of girls that has been reported by others.3' In retrospect, our decision to defer irradiation in those under 2 years old possibly contributed to these results, as these children received prolonged intrathecal chemotherapy as well as irradiation. New regimens for this age group are clearly indicated.
Our results also show that younger children are also more likely to develop abnormalities on computed tomography. It is difficult to compare our incidence of abnormalities with those reported by others because the details of treatment vary; for example, one of the highest rates of abnormalities has been reported in children receiving cranial irradiation and monthly intrathecal chemotherapy. 
